Baker Bros. Advisors’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Baker Bros. Advisors’s Portfolio LOGC Stock Details LOGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-139,105	Closed	-$38K	–	125
2022 Q3	$38K	Sell	139,105 -312,373	-69%	-$124K	﹤0.01%	115
2022 Q2	$158K	Hold	451,478	–	–	﹤0.01%	116
2022 Q1	$307K	Hold	451,478	–	–	﹤0.01%	117
2021 Q4	$1.04M	Hold	451,478	–	–	0.01%	115
2021 Q3	$2.07M	Hold	451,478	–	–	0.01%	111
2021 Q2	$2M	Hold	451,478	–	–	0.01%	110
2021 Q1	$3.29M	Hold	451,478	–	–	0.01%	106
2020 Q4	$3.44M	Buy	+451,478	New	+$3.02M	0.01%	99

Baker Bros. Advisors's LOGC Position: Q4 2022 in Review

Baker Bros. Advisors sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q4 2022, closing a stake of 139,105 shares — an estimated $38K sold.

Baker Bros. Advisors first reported a position in LOGC in Q4 2020 and held it in 8 quarters. The position peaked at $3.44M in Q4 2020. 0 funds tracked by Wall St. Rank hold LOGC as of Q4 2022.

Baker Bros. Advisors reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Baker Bros. Advisors sold 139,105 LogicBio Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $38K.
Baker Bros. Advisors first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q4 2020 and held it in 8 quarters.
Baker Bros. Advisors's LogicBio Therapeutics, Inc. Common Stock position peaked at $3.44M in Q4 2020.
0 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Baker Bros. Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.